Wu Zhuang

机构：XinHua Hospital, Fujian Provincial Cancer Hospital

发表论文 44 篇 · 总被引 895 次 · h-index 13

代表论文

• Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial (2021 · Journal of Thoracic Oncology · 被引 284)
• Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial (2024 · Nature Medicine · 被引 128)
• Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC (2025 · New England Journal of Medicine · 被引 60)
• Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study (2024 · Journal of Thoracic Oncology · 被引 51)
• Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study (2020 · Translational Lung Cancer Research · 被引 39)
• Simulation of hydrogen leakage diffusion behavior in confined space (2023 · International Journal of Hydrogen Energy · 被引 32)